Capvizr
THE DEAL, AT A GLANCE

Tempest Therapeutics

1/4 explanations supported
01
Immune cellsTherapy research
Cell therapy development
What it doesTempest develops in-body CAR-T therapies intended to treat autoimmune diseases or cancer.Source-grounded · automated review · Explore ↗

Checked 2026-09-11 · Review due 2026-09-18

Read supporting source ↗
Tempest is a clinical-stage CAR-T…
02Who is involvedEvidence still neededOpen review status ↗

Supported as a missing explanation. Document 0 names no investors, lenders, arrangers, or Series A roles.

03What happenedEvidence still neededOpen review status ↗

Supported as a missing explanation. The only September 11, 2026 financing-like item in document 0 is 'Tempest Therapeutics Announces Up to $7.5 Million Private Placement,' not a Series A round. The amount is a private placement amount, not a valuation.

04Why it mattersEvidence still neededOpen review status ↗

Supported. Because the supplied document does not establish a Series A event, Series A-specific business significance cannot be grounded. Any relevance interpretation would need to be limited to the private placement or the company's CAR-T business, not the target Series A.

Click a part to explore its evidence. Unsupported imagery is withheld rather than guessed.Original record source ↗

Tempest Therapeutics · Financing Record

Explore source-linked visual explanations for Tempest Therapeutics. Unsupported claims are withheld while source review continues.

Record 12083 · Recorded date: 2026-09-11

Explore company records →
Free weekday briefing

Know which funding rounds matter before the first call.

Source-linked rounds, lead investors, and the signal behind the capital. One five-minute read.

Free · Unsubscribe anytime